ANN ARBOR , Mich., Sept. 27, 2021 /PRNewswire/ -- Sartorius, a
leading international partner of life science research and the
biopharmaceutical industry, is expanding its presence in
Michigan. Sartorius will open a
new 130,000-square-foot (12,000-square-meter) state-of-the art
plant in Ann Arbor in late
2023.
"The new facility will consolidate existing business
operations in Washtenaw
County to create a center of excellence in Ann Arbor for the Laboratory and Bioprocess
Products and Services in North
America, which focus on providing innovative solutions to
help customers develop drugs that cure, prevent, and halt the
progression of diseases," said Mary
Lavin, President of Sartorius North America.
Sartorius will have an anchoring presence in the Tech Loop at
the Ann Arbor Research Park and add a flagship site in North America. To this end, the company has
purchased over 15 acres of land which provides sufficient space for
further expansion. The project is expected to create 160 jobs over
three years. These jobs will include product development,
operations, and other support functions.
Demand for innovative technologies used in the development and
production of biopharmaceuticals continues to grow rapidly. The
Ann Arbor site is an integral part
of Sartorius' ongoing worldwide expansion, enabling Sartorius to
scale up its operations and capabilities in the Ann Arbor biotech hub. By 2025, Sartorius will
more than double capacities for its key product groups.
This press release
contains forward-looking statements about the future development of
the Sartorius Group. Forward-looking statements are subject to
known and unknown risks, uncertainties and other factors that could
cause actual results to differ materially from those expressed or
implied by such statements. Sartorius assumes no liability for
updating such statements in light of new information or future
events.
|
A profile of Sartorius
The Sartorius Group is a leading international partner of life
science research and the biopharmaceutical industry. With
innovative laboratory instruments and consumables, the Group's Lab
Products & Services Division concentrates on serving the needs
of laboratories performing research and quality control at pharma
and biopharma companies and those of academic research institutes.
The Bioprocess Solutions Division with its broad product portfolio
focusing on single-use solutions helps customers to manufacture
biotech medications and vaccines safely and efficiently. The Group
has been annually growing by double digits on average and has been
regularly expanding its portfolio by acquisitions of complementary
technologies. In fiscal 2020, the company earned sales revenue of
some 2.34 billion euros. At the end of 2020, nearly 11,000
people were employed at the Group's approximately
60 manufacturing and sales sites, serving customers around the
globe. https://www.sartorius.com/en
Follow Sartorius on Twitter and on LinkedIn.
Contact:
Petra Kirchhoff
Head of Corporate Communications & Investor Relations
+49 (0)551 308 1686
petra.kirchhoff@sartorius.com
View original
content:https://www.prnewswire.com/news-releases/sartorius-to-expand-business-operations-in-north-america-301385308.html
SOURCE Sartorius AG